Skip to content
MarketScale
‹ Back to Industries

Sciences

NASA Scrubs First Test Flight of Moon Rocket After Engine Fault

(Bloomberg) — NASA is delaying the debut launch of its new massive rocket due to an issue with one of the rocket’s main engines in another setback for its plan to orbit the moon and return to Earth. The Space Launch System, or SLS, rocket launch which was expected early Monday will be rescheduled, the…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share
NASA Scrubs First Test Flight of Moon Rocket After Engine Fault

Key takeaways

01

(Bloomberg) — NASA is delaying the debut launch of its new massive rocket due to an issue with one of the rocket’s main engines in another setback for its plan to orbit the moon and return to Earth.

02

The Space Launch System, or SLS, rocket launch which was expected early Monday will be rescheduled, the…

(Bloomberg) — NASA is delaying the debut launch of its new massive rocket due to an issue with one of the rocket’s main engines in another setback for its plan to orbit the moon and return to Earth.

The Space Launch System, or SLS, rocket launch which was expected early Monday will be rescheduled, the space agency said. It could be pushed several days or even multiple weeks.

Official confirmation of the delay came after the space agency spent the early morning hours investigating issues including a potential crack in the material in the main body of the rocket as well as a possible temperature issue with one of the main engines, officials said early Monday. Those came after engineers examined and resolved a suspected leak affecting the hydrogen tanking process.

The uncrewed mission, called Artemis I, will be the first major flight in NASA’s ambitious plan to send the first woman and the first person of color to the lunar surface as early as 2025. Artemis I is aimed at testing out the SLS, made by Boeing Co., and a new deep-space crew capsule called Orion that was developed by Lockheed Martin Corp.

When Artemis I does launch, SLS will be sending Orion on a 42-day mission, along with a host of payloads and sensors to track the journey. The capsule is tasked with inserting itself into lunar orbit and entering deep space before returning to Earth in the Pacific Ocean off San Diego.

The Space Launch System already is more than five years behind schedule. It has been in development for roughly a decade, slowed by a myriad of delays and cost overruns. Development costs of the program have soared from an original $7 billion to about $23 billion, according to an estimate by the Planetary Society.

If successful, the Artemis program — named for the twin sister of the god Apollo in Greek mythology — will see the return of people to the lunar surface for the first time in 50 years. No one has visited the moon since Apollo 17 in December 1972.

More stories like this are available on bloomberg.com.

©2022 Bloomberg L.P.

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences